Administration of antineoplastic agents together with an embolizing vehicle. This allows slow release of the agent as well as obstruction of the blood supply to the neoplasm.
Ethyl ester of iodinated fatty acid of poppyseed oil. It contains 37% organically bound iodine and has been used as a diagnostic aid (radiopaque medium) and as an antineoplastic agent when part of the iodine is 131-I. (From Merck Index, 11th ed)
A preparation of oil that contains covalently bound IODINE. It is commonly used as a RADIOCONTRAST AGENT and as a suspension medium for CHEMOTHERAPEUTIC AGENTS.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
Tumors or cancer of the LIVER.
Sterile, gelatin-base surgical sponge applied topically as an adjunct to hemostasis when the control of bleeding by conventional procedures is ineffective to reduce capillary ooze or is impractical. (From AMA Drug Evaluations Annual, 1994, p797)
A branch of the celiac artery that distributes to the stomach, pancreas, duodenum, liver, gallbladder, and greater omentum.
A polymer prepared from polyvinyl acetates by replacement of the acetate groups with hydroxyl groups. It is used as a pharmaceutic aid and ophthalmic lubricant as well as in the manufacture of surface coatings artificial sponges, cosmetics, and other products.
Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease.
Minimally invasive procedures guided with the aid of magnetic resonance imaging to visualize tissue structures.
A method of hemostasis utilizing various agents such as Gelfoam, silastic, metal, glass, or plastic pellets, autologous clot, fat, and muscle as emboli. It has been used in the treatment of spinal cord and INTRACRANIAL ARTERIOVENOUS MALFORMATIONS, renal arteriovenous fistulas, gastrointestinal bleeding, epistaxis, hypersplenism, certain highly vascular tumors, traumatic rupture of blood vessels, and control of operative hemorrhage.
Small uniformly-sized spherical particles, of micrometer dimensions, frequently labeled with radioisotopes or various reagents acting as tags or markers.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Excision of all or part of the liver. (Dorland, 28th ed)
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.
Removal of tissue with electrical current delivered via electrodes positioned at the distal end of a catheter. Energy sources are commonly direct current (DC-shock) or alternating current at radiofrequencies (usually 750 kHz). The technique is used most often to ablate the AV junction and/or accessory pathways in order to interrupt AV conduction and produce AV block in the treatment of various tachyarrhythmias.
A short thick vein formed by union of the superior mesenteric vein and the splenic vein.
Unstable isotopes of yttrium that decay or disintegrate emitting radiation. Y atoms with atomic weights 82-88 and 90-96 are radioactive yttrium isotopes.
The minimum acceptable patient care, based on statutes, court decisions, policies, or professional guidelines.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
A branch of the external carotid artery which distributes to the deep structures of the face (internal maxillary) and to the side of the face and nose (external maxillary).
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Gauze material used to absorb body fluids during surgery. Referred to as GOSSYPIBOMA if accidentally retained in the body following surgery.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure.
Insertion of a catheter into a peripheral artery, vein, or airway for diagnostic or therapeutic purposes.
The transference of a part of or an entire liver from one human or animal to another.
An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.
Compounds that include the amino-N-phenylamide structure.
Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed)
Substances used to allow enhanced visualization of tissues.
A method of delineating blood vessels by subtracting a tissue background image from an image of tissue plus intravascular contrast material that attenuates the X-ray photons. The background image is determined from a digitized image taken a few moments before injection of the contrast material. The resulting angiogram is a high-contrast image of the vessel. This subtraction technique allows extraction of a high-intensity signal from the superimposed background information. The image is thus the result of the differential absorption of X-rays by different tissues.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Organic salts and esters of benzenesulfonic acid.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
The pathological process occurring in cells that are dying from irreparable injuries. It is caused by the progressive, uncontrolled action of degradative ENZYMES, leading to MITOCHONDRIAL SWELLING, nuclear flocculation, and cell lysis. It is distinct it from APOPTOSIS, which is a normal, regulated cellular process.
Delivery of drugs into an artery.
Clinical protocols used to inhibit the growth or spread of NEOPLASMS.
Use or insertion of a tubular device into a duct, blood vessel, hollow organ, or body cavity for injecting or withdrawing fluids for diagnostic or therapeutic purposes. It differs from INTUBATION in that the tube here is used to restore or maintain patency in obstructions.
Abnormal passage communicating with the STOMACH.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
A malignant tumor arising from the epithelium of the BILE DUCTS.
The circulation of BLOOD through the LIVER.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
Examination of the portal circulation by the use of X-ray films after injection of radiopaque material.
Radiography of blood vessels after injection of a contrast medium.
Prospective patient listings for appointments or treatments.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
Experimentally induced tumors of the LIVER.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
Tumors or cancer of the BILE DUCTS.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Passages within the liver for the conveyance of bile. Includes right and left hepatic ducts even though these may join outside the liver to form the common hepatic duct.
Care alleviating symptoms without curing the underlying disease. (Stedman, 25th ed)
Radiotherapy where there is improved dose homogeneity within the tumor and reduced dosage to uninvolved structures. The precise shaping of dose distribution is achieved via the use of computer-controlled multileaf collimators.
Any of a group of polysaccharides of the general formula (C6-H10-O5)n, composed of a long-chain polymer of glucose in the form of amylose and amylopectin. It is the chief storage form of energy reserve (carbohydrates) in plants.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.

Tumour ablation and hepatic decompensation rates in multi-agent chemoembolization of hepatocellular carcinoma. (1/507)

Thirty-seven cirrhotic patients with 62 hepatocellular carcinoma (HCC) foci--most Child-Pugh class B or C and/or with large, inoperable tumours--underwent 148 sessions of transcatheter arterial chemoembolization (TACE) using lipiodol, doxorubicin and cisplatin. Treatment efficacy was assessed by serial hepatic arteriography in 34/37 (91.9%) patients and abdominal CT scanning in 3/37 (8.1%) patients. Child-Pugh status was determined prior to each treatment session. Varying degrees of control of tumour neovascularity occurred for a median 390 days (range 90 to > 1680 days) in 33/34 (97.1%) patients in whom progress hepatic arteriography was performed. Ablation of tumour neovascularity occurred in 6/6 (100%), 4/12 (33.3%) and 6/16 (37.5%) patients with HCC diameters < 4 cm, 4-7 cm and > 8 cm, respectively (p < 0.02). Significantly more sessions were required for ablation of larger tumours (p < 0.05). Recurrent HCC was detected in 50% of patients after a median 240 days (range 60-1120 days). Deterioration in Child-Pugh status followed a session of TACE on 19/148 (12.8%) occasions but resulted in unscheduled hospitalization on only 4/148 (2.7%) occasions, the highest incidence (8.3%) in Child-Pugh C patients. Actuarial survival was 27/36 (75.0%) at 6 months, 17/34 (50.0%) at 12 months, 14/34 (41.2%) at 18 months, 9/31 (29.0%) at 24 months and 4/27 (14.8%) at 36 months. Multi-agent TACE with lipiodol, doxorubicin and cisplatin provides a useful anti-tumour effect, even in cirrhotic patients with large HCCs. The incidence of clinically significant deterioration in hepatic function due to ischaemia of non-tumorous liver is acceptably low, even in Child-Pugh C patients.  (+info)

Medullary thyroid carcinoma with multiple hepatic metastases: treatment with transcatheter arterial embolization and percutaneous ethanol injection. (2/507)

A 54-year-old man with medullary thyroid carcinoma in the thyroid gland was unable to undergo total thyroidectomy because the tumor had invaded the mediastinum. Radiation therapy and chemotherapy were given. Seven years later, intractable diarrhea and abdominal pain appeared, and computed tomography demonstrated hypervascular tumors in the thyroid gland and in the liver. The tumors were successfully treated with percutaneous ethanol injection to a lesion in the thyroid gland and transcatheter arterial embolization followed by percutaneous ethanol injection to tumors in the liver. Transcatheter arterial embolization and percutaneous ethanol injection may be valuable in treating medullary thyroid carcinoma.  (+info)

Feasibility and toxicity of chemoembolization for children with liver tumors. (3/507)

PURPOSE: To determine the feasibility, toxicity, and efficacy of hepatic arterial chemoembolization (HACE) in pediatric patients with refractory primary malignancies of the liver. PATIENTS AND METHODS: Six patients with hepatoblastoma (HB), three with hepatocellular carcinoma (HCC), and two with undifferentiated sarcoma of the liver were treated with HACE every 2 to 4 weeks until their tumors became surgically resectable or they showed signs of disease progression. All but one newly diagnosed patient with HCC had previously received systemic chemotherapy. RESULTS: All patients with HB and HCC responded to HACE, as measured by imaging studies and alpha-fetoprotein levels. Surgical resection (complete or microscopic residual disease) was feasible in five of 11 patients, and three patients remain alive with no evidence of disease. Elevated liver transaminase and bilirubin levels were seen after each one of the 46 courses of HACE. Other toxicities included fever, pain, nausea, vomiting, and transient coagulopathy. CONCLUSION: HACE is feasible, well tolerated, and effective in inducing surgical resectability of primary hepatic tumors in children.  (+info)

Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. (4/507)

OBJECTIVE: To assess the influence of preoperative portal vein embolization (PVE) on the long-term outcome of liver resection for colorectal metastases. SUMMARY BACKGROUND DATA: Preoperative PVE of the liver induces hypertrophy of the remnant liver and increases the safety of hepatectomy. METHODS: Thirty patients underwent preoperative PVE and 88 patients did not before resection of four or more liver segments. PVE was performed when the estimated rate of remnant functional liver parenchyma (ERRFLP) assessed by CT scan volumetry was less than 40%. RESULTS: PVE was feasible in all patients. There were no deaths. The complication rate was 3%. The post-PVE ERRFLP was significantly increased compared with the pre-PVE value. Liver resection was performed after PVE in 19 patients (63%), with surgical death and complication rates of 4% and 7% respectively. PVE increased the number of resections of more than four segments by 19% (17/88). Actuarial survival rates after hepatectomy with or without previous PVE were comparable: 81%, 67%, and 40% versus 88%, 61%, and 38% at 1, 3, and 5 years respectively. CONCLUSIONS: PVE allows more patients with previously unresectable liver tumors to benefit from resection. Long-term survival is comparable to that after resection without PVE.  (+info)

Malignant insulinoma which expressed a unique creatine kinase isoenzyme: clinical value of arterial embolization as a palliative therapy. (5/507)

A 76-year-old man with hypoglycemic coma was diagnosed as malignant insulinoma with multiple hepatic metastases. Embolization was done for two-thirds of the hepatic mass and it rapidly lowered the serum immunoreactive insulin. He was discharged without medication and has been free from hypoglycemia. After the embolization, the serum creatine kinase (CK) level increased transiently although there was no evidence of myocardial infarction. On electrophoresis, the CK activity showed an abnormal peak, suggesting mitochondrial CK. CK release after embolization has been reported in only a few cases with endocrine tumors, which might indicate some relationship between active energy metabolism and mitochondrial CK.  (+info)

Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. (6/507)

OBJECTIVE: To evaluate the current knowledge on the risk factors for recurrence, efficacy of adjuvant therapy in preventing recurrence, and the optimal management of recurrence after resection of hepatocellular carcinoma (HCC). SUMMARY BACKGROUND DATA: The long-term prognosis after resection of HCC remains unsatisfactory as a result of a high incidence of recurrence. Prevention and effective management of recurrence are the most important strategies to improve the long-term survival results. METHODS: A review of relevant English articles was undertaken based on a Medline search from January 1980 to July 1999. RESULTS: Pathologic factors indicative of tumor invasiveness such as venous invasion, presence of satellite nodules, large tumor size, and advanced pTNM stage, are the best-established risk factors for recurrence. Active hepatitis activity in the nontumorous liver and perioperative transfusion also appear to enhance recurrence. Recent molecular research has identified tumor biologic factors such as the proliferative and angiogenic activities of the tumor as new risk factors for recurrence. There is a lack of convincing evidence for the efficacy of neoadjuvant or adjuvant therapy in preventing recurrence. Retrospective studies suggested that postoperative hepatic arterial chemotherapy might improve disease-free survival, but results were conflicting. For the management of postoperative recurrence, studies have consistently indicated that surgical resection should be the treatment of choice for localized recurrence, be it in the liver remnant or extrahepatic organs. Transarterial chemoembolization and percutaneous ethanol injection are widely used to prolong survival in patients with unresectable intrahepatic recurrence, and combined therapy with these two modalities may offer additional benefit. CONCLUSIONS: Knowledge of the risk factors for postoperative recurrence provides a basis for logical approaches to prevention. Minimal surgical manipulation of tumors to prevent tumor cell dissemination, avoidance of perioperative blood transfusion, and suppression of chronic hepatitis activity in the liver remnant are strategies that may be useful in preventing recurrence. The efficacy of postoperative adjuvant regional chemotherapy deserves further evaluation. New concepts on the influence of tumor biologic factors such as angiogenic activity on recurrence of HCC suggest a potential role of novel approaches such as antiangiogenesis for adjuvant therapy in the future. Currently, the most realistic approach in prolonging survival after resection of HCC is early detection and aggressive management of recurrence. Randomized trials are needed to define the roles of various treatment modalities for recurrence and the benefit of multimodality therapy.  (+info)

Uterine fibroid embolization. (7/507)

Interventional radiologists have performed uterine artery embolization to treat women with emergency uterine bleeding since the 1970s. In this procedure, the physician guides a small angiographic catheter into the uterine arteries and injects a stream of tiny particles that decreases blood flow to the uterus. It is now considered a safe and highly effective nonsurgical treatment of women with symptomatic uterine fibroid tumors. Uterine fibroid embolization has several advantages over conventional hormonal suppression and surgical procedures, including avoidance of the side effects of drug therapy and the physical and psychologic trauma of surgery. In addition, after uterine fibroid embolization, patients can normally resume their usual activities several weeks earlier than they can after hysterectomy. Along with hysteroscopic resection, myolysis and laparoscopic myomectomy, uterine fibroid embolization widens treatment options for patients who desire to avoid hysterectomy.  (+info)

Nonsurgical treatment of hepatocellular carcinoma. (8/507)

1. Outcome from nonsurgical treatment is directly related to stage of hepatocellular cancer (HCC) and degree of liver function impairment. 2. Ablative percutaneous procedures, such as alcohol injection or radiofrequency thermal therapy, are most effective in the destruction of solitary tumors of 3 cm or less. 3. In most cases, nonsurgical treatments are not curative, but may slow tumor progression and can provide palliation. 4. Arterial embolization or chemoembolization has an antitumor effect, but it has not been shown to affect patient outcome. 5. Radiation therapy, chemotherapy, hormonal manipulation, and interferon have not been consistently effective in HCC. 6. Ablative procedures, embolization, and systemic chemotherapy should be avoided in patients with advanced cirrhosis.  (+info)

TY - JOUR. T1 - A case of hepatocellular carcinoma with skin injury of the upper abdominal wall after transcatheter arterial chemoembolization. T2 - A case report. AU - Kanzaki, Hiromitsu. AU - Nouso, Kazuhiro. AU - Miyahara, Koji. AU - Kajikawa, Naoko. AU - Kobayashi, Sayo. AU - Sakakihara, Ichiro. AU - Iwadow, Shota. AU - Uematsu, Shuji. AU - Okamoto, Ryoichi. AU - Shiraga, Kunihiro. AU - Mizuno, Motowo. AU - Araki, Yasuyuki. PY - 2009/9/1. Y1 - 2009/9/1. N2 - Introduction: Transcatheter arterial chemoembolization has been widely used to treat advanced hepatocellular carcinoma that cannot be treated by local ablation therapies or surgical resection. The effectiveness of transcatheter arterial chemoembolization in prolonging survival has been well established, and approximately one third of newly discovered hepatocellular carcinoma patients were repeatedly treated by transcatheter arterial chemoembolization in Japan. Various kinds of complications have been reported, and many of which are ...
Hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver. Chronic hepatitis B infection is the common etiology for the development of HCC. Transcatheter arterial chemoembolization (TACE) is the traditional method for the palliative management of patients with HCC. Few previous studies had demonstrated that the serum level of anticancer drug from patients treated by TACE was similar to those treated by systemic chemotherapy. Since systemic chemotherapy may have the possibility to influence patients general defense ability, hepatitis B virus may reactivate after chemotherapy. There is no study to investigate the possibility of TACE in the reactivation of hepatitis B virus. This project will collect 20 patients with HCC caused by hepatitis B who are planned to be treated by TACE. Quantitative determination of viral load in blood will be performed before TACE, the first and the third month after TACE to investigate the influence of TACE on hepatitis B virus replication. This ...
TY - JOUR. T1 - Evaluation of Hepatocellular Carcinoma Tumor Response After Transcatheter Arterial Chemoembolization Using Gadobenate Dimeglumine-Enhanced Liver Magnetic Resonance. AU - Chu, Linda Chi Hang. AU - Pozzessere, Chiara. AU - Corona Villalobos, Celia. AU - Castaños, Sandra. AU - Rastegar, Neda. AU - Halappa, Vivek. AU - Bonekamp, Susanne. AU - Emurano, Emi. AU - Kamel, Ihab R. PY - 2016/9/27. Y1 - 2016/9/27. N2 - OBJECTIVE: Use of gadobenate dimeglumine-enhanced liver magnetic resonance (MR) for evaluation of hepatocellular carcinoma tumor response after transcatheter arterial chemoembolization (TACE). METHODS: Forty-five patients with hepatocellular carcinoma were imaged with multiphase gadobenate dimeglumine-enhanced MR examination at baseline and 1-month follow-up after TACE. Nodule size, enhancement, and apparent diffusion coefficient were measured for both examinations by 2 reviewers. Changes in tumor nodule size, enhancement, and apparent diffusion coefficient were evaluated ...
Transcatheter arterial chemoembolization (also called transarterial chemoembolization or TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumors blood supply. Small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways. The radiotherapeutic analogue (combining radiotherapy with embolization) is called radioembolization or selective internal radiation therapy (SIRT). TACE derives its beneficial effect by two primary mechanisms. Most tumors within the liver are supplied by the proper hepatic artery, so arterial embolization preferentially interrupts the tumors blood supply and stalls growth until neovascularization. Secondly, focused administration of chemotherapy allows for delivery of a higher dose to the tissue while simultaneously reducing systemic exposure, ...
TY - JOUR. T1 - Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma. AU - Park, Hana. AU - Jung, Jae Hyung. AU - Jung, Min Kyung. AU - Shin, Eui Cheol. AU - Ro, Simon Weonsang. AU - Park, Jeon Han. AU - Kim, Do Young. AU - Park, Jun Yong. AU - Han, Kwang Hyub. PY - 2020/3/1. Y1 - 2020/3/1. N2 - Background: Regulatory T cell (Treg) plays an essential role in regulating anti-tumor immunity. The aim of this study was to investigate the effect of transarterial chemoembolization (TACE) on Treg in hepatocellular carcinoma (HCC) patients. Method: The frequency of peripheral blood Tregs in 27 HCC patients who underwent TACE were measured at baseline and 1 month after TACE. The frequency of peripheral blood Tregs at baseline were compared with those in 23 healthy controls. Tregs were further classified into three subpopulations [Treg (I), Treg (II), Treg (III)] based on expression levels or markers and their function. The ...
2016 SIR Purpose To measure transarterial chemoembolization utilization and survival benefit among patients with hepatocellular carcinoma (HCC) in the Surveillance, Epidemiology, and End Results (SEER) patient population. Materials and Methods A retrospective study identified 37,832 patients with HCC diagnosed between 1991 and 2011. Survival was estimated by Kaplan-Meier method and compared by log-rank test. Propensity-score matching was used to address an imbalance of covariates. Results More than 75% of patients with HCC did not receive any HCC-directed treatment. Transarterial chemoembolization was the most common initial therapy (15.9%). Factors associated with the use of chemoembolization included younger age, more HCC risk factors, more comorbidities, higher socioeconomic status, intrahepatic tumor, unifocal tumor, vascular invasion, and smaller tumor size (all P < .001). Median survival was improved in patients treated with chemoembolization compared with those not treated with ...
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as doxorubicin hydrochloride and mitomycin C, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoembolization kills tumor cells by carrying drugs directly into the tumor and blocking blood flow to the tumor. Giving sorafenib tosylate before and after chemoembolization may kill more tumor cells.. PURPOSE: This phase II trial is studying the side effects and how well giving sorafenib tosylate before and after hepatic arterial chemoembolization with doxorubicin hydrochloride and mitomycin C works in treating patients with localized liver cancer that cannot be removed by surgery. ...
In the current issue, Kim et al. conducted a retrospective study comparing scheduled repetition of chemoembolization with on demand approach [6]. In multivariate analysis, scheduled repetition of chemoembolization was an independent favorable prognostic factor for survival. However, in the manuscript, there were no supporting data how scheduled repetition of chemoembolization led to survival improvement. How many patients had residual viable tumor on scheduled 2nd chemoembolization? Was scheduled 2nd chemoembolization significantly decreased the rate of locally invasive recurrence or chemoembolization failure? Was scheduled 2nd chemoembolization decreased remote intrahepatic recurrence or distant metastasis rate? They reported that treatment strategy (scheduled vs. on-demand) was not associated with recurrence-free survival (39.7% vs. 49.2% at 1 year, P=0.26) and local recurrence-free survival (68.3% vs. 66.8% at 1 year, P=0.38). Retrospective series are prone to selection bias. I believe there ...
Background: To compare the efficacy and safety of long- versus short-interval of transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (HCC) patients.. Methods: This retrospective analysis enrolled 574 patients with unresectable HCC who underwent at least two sessions of TACE between January 2007 and December 2014. The patients were divided into a short-interval group (SIG) and a long-interval group (LIG) based on the median TACE interval of the first two sessions. Propensity score matching (PSM) identified 476 patients for a comparison of overall survival (OS) and safety.. Results: Before matching, the LIG had a longer OS than the SIG (Median: 12.1 vs. 8.7 months; P = 0.003). After matching, median OS in the SIG and LIG were 9.1 and 14.2 months (P , 0.001). The 1-, 2-, and 3-year survival rates were 37.5%, 17.1%, and 9.9% for SIG and 50.1%, 19.3%, and 11.6% for LIG, respectively. The TACE interval was an independent prognostic factor for OS. The LIG had a longer OS ...
Clinical trial focusing on transarterial chemoembolization. Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer
Both transcatheter arterial chemoembolization (TACE) and percutaneous ethanol injection therapy (PEI) have proven their efficacy in patients with unresectable hepatocellular carcinoma (HCC): TACE mainly in large lesions or disseminated disease and PEI in solitary lesions smaller than 3 cm. Although
The aim of this study was to determine the clinical benefit of transhepatic arterial chemoembolization (TACE) with or without recombinant human adenovirus type 5 (H101) administration for the treatment of patients with hepatocellular carcinoma (HCC). Tumor response, progression-free survival (PFS), and overall survival(OS) were retrospectively evaluated in consecutive patients with unresectable HCC who received TACE with or without H101 between April 2012 and April 2013. Patients with unresectable HCC were treated with transarterial injection of H101 with TACE (H101 group, n = 87) or TACE alone (control group, n = 88). Clinicopathological features were similar between the groups. Treatment response was significantly different between the groups (P = 0.01). In the H101 group, 25 patients demonstrated a complete response (CR, 28.7 %); 28 patients, a partial response (PR, 32.2 %); 23 patients, stable disease (SD, 26.4 %); and 11 patients, progressive disease (PD, 12.6 %). In the control group, 13 patients
Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study
Background and Aim: This study aimed to evaluate the therapeutic efficacy and safety of repeated transarterial chemoembolization (TACE) with additional radiation therapy (RT) in hepatocellular carcinoma (HCC) with portal vein (PV) invasion.. Methods: We performed survival analysis of consecutive HCC patients with PV invasion according to the treatment modalities after stratification by the degree of PV invasion and liver function retrospectively.. Results: During 2005, 281 patients were newly diagnosed to have HCC with PV invasion at our institution. Repeated TACE or transarterial chemoinfusion (TACI) was performed in 202 (71.9%) patients and additional RT was performed for PV invasion in 43 of them. A total of 281 patients had a median survival of 5.2 months and a 2-year survival rate (YSR) of 19.2%. Repeated TACE showed significant survival benefits compared with conservative management in patients with PV branch invasion; median survival and 2-YSR was 10.2 vs 2.3 months and 33.7% vs 0% in ...
This study is investigating the efficacy and safety of sorafenib alone versus in combination with transarterial chemoembolization (TACE) (doxorubicin +
Cripto-1 may act as an independent predictor for prognosis in hepatocellular carcinoma (HCC). However, the function of Cripto-1 in HCC cells and its response to postoperative transarterial chemoembolization (TACE) in HCC patients remains unclearly. Up-regulated Cripto-1 expression boosted the ability of cell proliferation, migration and invasion in HCC cells in vitro. While opposite results were observed in HCC cells with down-regulated Cripto-1 expression. Cripto-1 expression was correlated with epithelial-mesenchymal transition (EMT) relevant biomarkers. Furthermore, in high Cripto-1 expression patients, those with adjuvant TACE had favorable TTR and OS times. On contrary, adjuvant TACE may promote tumor recurrence but had no influence on OS time in patients with low Cripto-1 expression. In different subgroups of vascular invasion, larger tumor size or liver cirrhosis, patients with adjuvant TACE had longer TTR and OS times than those without TACE in patients with high Cripto-1 expression,
There was no difference in clinical background between these groups. Complete response to therapy was noted in 29 (96.3%) patients of the SBRT group, and in only one (3.3%) patient of the TACE group (P , 0.001). None of the patients developed acute hematologic toxicity of more than Common Terminology Criteria for Adverse Events Grade 3 during and after the treatment. Furthermore, none of the SBRT group developed radiation-induced liver damage. Disease-free survival of the 12 patients without previous HCC treatments in SBRT group was significantly superior to that in control group (15.7 months vs 4.2 months; P = 0.029). ...
AbstractWe aim to investigate the effects of postoperative adjuvant transarterial chemoembolization (TACE) on survival and recurrence in hepatocellular carcinoma (HCC) patients after radical resection. A total of 320 HCC patients underwent radical resection between January 2010 and January 2014 in Q
TY - JOUR. T1 - Regression of Hepatocellular Carcinoma With Right Atrial Extension After Sorafenib and Transarterial Chemoembolization. AU - Subramanian, Madhu. AU - Singal, Amit G.. AU - Yopp, Adam C.. PY - 2012/10/1. Y1 - 2012/10/1. UR - UR - U2 - 10.1016/j.cgh.2012.06.031. DO - 10.1016/j.cgh.2012.06.031. M3 - Article. C2 - 22813441. AN - SCOPUS:84866445106. VL - 10. SP - e83-e84. JO - Clinical Gastroenterology and Hepatology. JF - Clinical Gastroenterology and Hepatology. SN - 1542-3565. IS - 10. ER - ...
Transarterial chemoembolization may be offered as a main treatment for liver cancer or for people waiting for a transplant. Learn about TACE for liver cancer.
This study is investigating transarterial chemoembolization containing arsenic trioxide in the treatment of hepatocellular carcinoma.
Application of poly-lactide-co-glycolide-microspheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma
TY - JOUR. T1 - [A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy].. AU - Mukai, Ryota. AU - Wada, Hiroshi. AU - Tomimaru, Yoshito. AU - Hama, Naoki. AU - Kawamoto, Koichi. AU - Kobayashi, Shogo. AU - Eguchi, Hidetoshi. AU - Umeshita, Koji. AU - Doki, Yuichiro. AU - Mori, Masaki. AU - Nagano, Hiroaki. PY - 2013/11. Y1 - 2013/11. N2 - We report a case of multiple intrahepatic recurrence of hepatocellular carcinoma( HCC) that was successfully treated with transcatheter arterial chemoembolization( TACE) and sorafenib therapy. A 73-year-old man was diagnosed as having multiple intrahepatic recurrence in segment 2 (S2) and segment 7 (S7) of the liver on abdominal computed tomography (CT) scans 4 years after he underwent liver resection. He was treated with 5 cycles of TACE. Two years and 6 months after the initial TACE, we found that the patient had become refractory to TACE, and therefore, ...
TY - JOUR. T1 - Parametric response mapping of dynamic CT as an imaging biomarker to distinguish viability of hepatocellular carcinoma treated with transcatheter arterial chemoembolization. AU - Choi, Seung Joon. AU - Kim, Jonghoon. AU - Seo, Jongbum. AU - Kim, Hyung Sik. AU - Lee, Jong Min. AU - Park, Hyunjin. PY - 2014/6. Y1 - 2014/6. N2 - Purpose: Accurate assessment of viability of hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE) is important for therapy planning. The purpose of this study is to determine the diagnostic value of a novel image analysis method called parametric response mapping (PRM) in predicting viability of tumor in HCC treated with TACE for dynamic CT images. Methods: 35 patients who had 35 iodized-oil defect areas (IODAs) in HCCs treated with TACE were included in our study. These patients were divided into two groups, one group with viable tumors (n = 22) and the other group with non-viable tumors (n = 13) in the IODA. All patients ...
Transarterial chemoembolization (TACE) is a very well-known treatment used for non resectable hepatocellular carcinoma (HCC). After chemoembolization, pancreatitis is a known but uncommon complication, result from local cytotoxicity or pancreatic ischemia due to reflux of chemoembolic material into pancreatic arterial branches. In this manuscript, we present a case of mild and self-limited acute pancreatitis post-chemoembolization, with successful conservative treatment.. ...
Full Title MCT: A Multicenter Pilot Study of Nivolumab with Drug Eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma Purpose Liver cancers that cannot be surgically removed or treated with liver transplantation are sometimes treated with embolization. Chemoembolization is when doctors perform a procedure to send tiny glass beads with chemotherapy through the arteries supplying blood to the tumor, causing the tumor to die. This procedure has been shown to shrink tumors and allow patients with liver cancer to live longer.
The above FLIGHTPLAN FOR LIVER performance aspects reflect the results of four published journal articles1234 that used the FLIGHTPLAN FOR LIVER software or its prototype5.. 1 - Computed Analysis of Three-Dimensional Cone-Beam Computed Tomography Angiography for Determination of Tumor-Feeding Vessels During Chemoembolization of Liver Tumor: A Pilot Study - Deschamps et al. Cardiovasc Intervent Radiol. 2010.. 2 - Tracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using Three-Dimensional Cone-Beam CT Angiography - Minami et al. Liver Cancer. 2014.. 3 - Clinical utility and limitations of tumor-feeder detection software for liver cancer embolization. Iwazawa et al. European Journal of Radiology. 2013.. 4 - Comparison of the Number of Image Acquisitions and Procedural Time Required for Transarterial Chemoembolization of Hepatocellular Carcinoma with and without Tumor-Feeder Detection Software - Iwazawa et al. Radiology Research and Practice. ...
TY - JOUR. T1 - Fabrication of radiopaque drug-eluting beads based on Lipiodol/biodegradable-polymer for image-guided transarterial chemoembolization of unresectable hepatocellular carcinoma. T2 - Fabrication of radiopaque DEBs by Lipiodol/biodegradable-polymer for TACE of HCC. AU - Okamoto, Yutaka. AU - Hasebe, Terumitsu. AU - Bito, Kenta. AU - Yano, Kosaku. AU - Matsumoto, Tomohiro. AU - Tomita, Kosuke. AU - Hotta, Atsushi. N1 - Funding Information: This work was supported in part by a Grant-in-Aid for Scientific Research (A) (No. 19H00831 to A. H.), by Grant-in-Aid for Challenging Exploratory Research (No. 19K22067 to A. H.), by a Grant-in-Aid for Scientific Research (B) (No. 18H01726 to T. H.), and by a Grant-in-Aid for JSPS Research Fellow (No. 18J13148 to K. B.) from the Japan Society for the Promotion of Science (JSPS: KAKENHI). It was also supported in part by AMED , Japan under Grant Number A306TS . Publisher Copyright: © 2020 Elsevier Ltd. PY - 2020/5. Y1 - 2020/5. N2 - New ...
TY - JOUR. T1 - [Treatment of Hepatocellular Carcinoma with Drug-eluting Beads Chemoembolization and Liver Transplantation].. AU - Yoon, Hyun Hwa. AU - Jung, Young Kul. AU - Chung, Dong Hae. AU - Choi, Seung Joon. AU - Kim, Jeong Ho. AU - Kim, Keon Kuk. PY - 2012/11. Y1 - 2012/11. UR - U2 - 10.4166/kjg.2012.60.5.335. DO - 10.4166/kjg.2012.60.5.335. M3 - Article. C2 - 23311003. AN - SCOPUS:84887551777. VL - 60. SP - 335. EP - 338. JO - Zeitschrift für Induktive Abstammungs- und Vererbungslehre. JF - Zeitschrift für Induktive Abstammungs- und Vererbungslehre. SN - 0730-6512. IS - 5. ER - ...
to hear that the two tace procedures didnt work for you. I can only imagine how you are feeling. My Mom passed away from bile duct cancer and it was a long road so I can understand what you are going through...and want you to know my heart goes out to you and I am praying and pulling for only the best for you and your health. My friend has been very successful with the tace procedure. Im sad to read it didnt help you. Have you thought about getting another opinion? I think that might be a good idea. This is your life, dont ever ever give up! Keep fighting the good fight! What state are you in? I am in Maryland. Hopkins is a great place and can do many wonderful things for people, I hope you will consider another opinion. Please write me if you need a friend at [email protected] I would love to be support for you. Sincerely, Angel. Many hugs! I am pulling for you and praying for the best for you! ...
PurposeThis study was designed to analyze retrospectively the performance of cone-beam computed tomography (CBCT) hepatic arteriography in depicting tumors and their feeders and to investigate the related determining factors in chemoembolization for hepatocellular carcinoma (HCC).MethodsEighty-six patients with 142 tumors satisfying the imaging diagnosis criteria of HCC were included in this study. The performance of CBCT hepatic arteriography for chemoembolization per tumor and per patient was evaluated using maximum intensity projection images alone (MIP analysis) or MIP combined with multiplanar reformation images (MIP + MPR analysis) regarding the following three aspects: tumor depiction, confidence of tumor feeder detection, and trackability of tumor feeders. Tumor size, tumor enhancement, tumor location, number of feeders, diaphragmatic motion, portal vein enhancement, and hepatic artery to parenchyma enhancement ratio were regarded as potential determining factors.ResultsTumors were ...
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by st
PURPOSE: To compare currently available non-three-dimensional methods (Response Evaluation Criteria in Solid Tumors [RECIST], European Association for Study of the Liver [EASL], modified RECIST [mRECIST[) with three-dimensional (3D) quantitative methods of the index tumor as early response markers in predicting patient survival after initial transcatheter arterial chemoembolization (TACE). MATERIALS AND METHODS: This was a retrospective single-institution HIPAA-compliant and institutional review board-approved study. From November 2001 to November 2008, 491 consecutive patients underwent intraarterial therapy for liver cancer with either conventional TACE or TACE with drug-eluting beads. A diagnosis of hepatocellular carcinoma (HCC) was made in 290 of these patients. The response of the index tumor on pre- and post-TACE magnetic resonance images was assessed retrospectively in 78 treatment-naïve patients with HCC (63 male; mean age, 63 years ± 11 [standard deviation]). Each response as
Embolization was performed, according to the authors, with doxorubicin drug-eluting LC Beads (Biocompatibles) and the particle size was determined by the interventional radiologist performing chemoembolization. Sixty one treated tumours were treated in 61 patients and were assessed for response to the drug-eluting beads. Out of these patients 39 (64%) were treated with 100-300µm particles and 22 patients were treated with 300-500µm.. All chemoembolization procedures were successful and there were no deaths related to the procedure. Patients were followed-up at one month and then every three months as outpatient visits and imaging.. At baseline patients in the 100-300µm and 300-500µm groups had similar tumour size distributions, said Padia et al. Although no statistically significant differences in tumour response by either the World Health Organization (WHO) or the European Association for the Study of the Liver (EASL) were seen, there were tendencies toward higher rates of complete ...
In this study, the mean OS for all patients was 80.7 ± 5.6 months, and the 1-, 3-, and 5-year median OS rates were 88.1%, 64.8%, and 49.9%, respectively. Recent studies in which patients with early HCC or HCC , 4 cm received TACE as the initial treatment modality have shown that the 1-, 3-, and 5-year survival rates were 89% to 100%, 63% to 81%, and 43% to 52%, respectively [33-37]. The results of our study are in line with those of these studies. Another study investigated the long-term survival of patients with HCC who met the Milan criteria and underwent RFA (n = 315) or TACE (n = 215) as an initial treatment. The two groups did not show any significant differences in terms of long-term survival rates (the 1-, 3-, and 5-year survival rates were 85%, 60%, and 41% for RFA, and 86%, 55%, and 36% for TACE, respectively) [33]. Recently, Kim et al. [7] reported that TACE can be a viable alternative treatment modality for small HCCs (, 2 cm) when RFA is not indicated, although RFA showed better ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Table 3: Comparison of Transcatheter Arterial Chemoembolization-Radiofrequency Ablation and Transcatheter Arterial Chemoembolization Alone for Advanced Hepatocellular Carcinoma with Macrovascular Invasion Using Propensity Score Analysis: A Retrospective Cohort Study
TY - JOUR. T1 - Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies. AU - Lewis, H. L.. AU - Ghasabeh, M. A.. AU - Khoshpouri, P.. AU - Kamel, Ihab R. AU - Pawlik, T. M.. PY - 2017/12/1. Y1 - 2017/12/1. N2 - Objective criteria to measure tumor response are a key tenet for assessment of treatment efficacy when evaluating a therapeutic modality. Several response criteria have been proposed including the Response Evaluation Criteria in Solid Tumors (RECIST), modified RECIST (mRECIST), RECIST 1-1, and European Association for the Study of the Liver (EASL) guidelines. Response following loco-regional therapies (LRT) can be particularly difficult to assess as post-treatment changes may not always relate to changes in lesion size. As imaging modalities and solid tumor therapies continue to advance, there has been growing recognition that measurement of actual tumoricidal activity may not always be related to tumor size, and accurate assessment of ...
This study aimed to evaluate the effect of stereotactic ablative radiotherapy (SABR) after incomplete transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) patients. The study enrolled 178 HCC patients initially treated with TACE between 2006 and 2011. Patients were included if they had Barcelona Clinic Liver Cancer stage 0 or A, ≤3 nodules with a total sum of longest diameter ≤10 cm, Child-Turcotte-Pugh score of ≤7, no major vessel invasion, and no extra-hepatic metastases. Twenty-four patients achieved a complete response to TACE (group 1). Among those with incomplete response, 47 patients received other curative treatments (group 2), 37 received SABR (group 3), and 70 received non-curative treatments (group 4). The 2-year overall survival (OS) rates for groups 1, 2, 3, and 4 were 88 %, 81 %, 73 %, and 54 %, respectively. The corresponding 5-year OS rates were 50 %, 58 %, 53 %, and 28 %, respectively. Patients treated with SABR after incomplete TACE had similar
Although transarterial chemoembolization (TACE) has been used extensively for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT), no consensus has been reached and an evidence base for practice is lacking. This meta-analysis evaluated the efficacy and safety of TACE for treatment of HCC with PVTT. Ovid Medline, EMBASE, Web of Knowledge, and Cochrane library databases were searched up to August 2012 for controlled trials assessing TACE in patients with PVTT. Data concerning the study design, characteristics of trials, and outcomes were extracted. Hazard ratio (HR) and 95% confidence interval (CI) were calculated using random effects models. Eight controlled trials involving 1601 HCC patients were included. TACE significantly improved the 6-month (HR, 0.41; 95% CI: 0.32-0.53; z, 6.28; p = 0.000) and 1-year (HR, 0.44; 95% CI: 0.34-0.57; z, 6.22; p = 0.000) overall survival of patients with PVTT compared with conservative treatment. Subgroup analyses showed that TACE was
TY - JOUR. T1 - Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. AU - Park, Yehyun. AU - Kim, Beom Kyung. AU - Park, Jun Yong. AU - Kim, Do Young. AU - Ahn, Sang Hoon. AU - Han, Kwang Hyub. AU - Yeon, Jong Eun. AU - Byun, Kwan Soo. AU - Kim, Hye Soo. AU - Kim, Ji Hoon. AU - Kim, Seung Up. N1 - Publisher Copyright: © 2019 The Author(s). Copyright: Copyright 2019 Elsevier B.V., All rights reserved.. PY - 2019/4/16. Y1 - 2019/4/16. N2 - Background: Hepatoma arterial-embolization prognostic (HAP) score and its modifications (modified HAP [mHAP] and mHAP-II), consisting of some or all of the following factors of tumor size, number, alpha-fetoprotein, bilirubin, and serum albumin, have been found to predict outcomes after trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). We investigated the feasibility of using HAP-related risk scores for dynamic risk assessment during repeated TACE. Methods: A ...
Prognostic role of ABO blood group in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization Qing Li,1,* Tao Wu,1,* Xiao-An Ma,2,* Li Jing,1 Li-Li Han,3 Hui Guo1 1Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China; 2Department of General Surgery, Xi’an Central Hospital, Xi’an, Shaanxi, People’s Republic of China; 3Department of Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China *These authors contributed equally to this work Background: The association of ABO blood group with prognosis of several malignancies has been established. However, its role in hepatocellular carcinoma (HCC) remains unclear.Patients and methods: In this study, we investigated the prognostic role of ABO blood group in unresectable HCC patients receiving transarterial chemoembolization (TACE) as
OP56 - A matched case-control study for the treatment of unresectable hepatocellular carcinoma (HCC): trans-arterial radioembolization (TARE) with 90Y glass microspheres plus sorafenib versus TARE ...
Purpose: This study was designed to evaluate the safety of chemotherapeutic infusion or chemoembolization by way of the cystic artery in patients with hepatocellular carcinoma (HCC) supplied exclusively by the cystic artery. Methods: Between Jan 2002 and Dec 2011, we performed chemotherapeutic infusion or chemoembolization using iodized oil for the treatment of 27 patients with HCC supplied exclusively by the cystic artery. Computed tomography (CT) scans, digital subtraction angiograms, and medical records were retrospectively reviewed by consensus. Results: The cystic artery originated from the main right hepatic artery in 24 (89 %) patients, from the right anterior hepatic artery in 2 (7 %) patients, and from the left hepatic artery in 1 (4 %) patient. Selective catheterization of the cystic artery was achieved in all patients. Superselection of tumor-feeding vessels from the cystic artery was achieved in 7 patients (26 %). Chemotherapeutic infusion was performed in 18 patients (67 %), and ...
TY - JOUR. T1 - Evaluation of posttreatment responseof hepatocellular carcinoma: comparisonof ultrasonography with second-generationultrasound contrast agent and multidetector CT. AU - Caruso, Giuseppe. AU - Meloni, Maria Franca. AU - Campisi, Antonella. AU - Salvaggio, Giuseppe. PY - 2010. Y1 - 2010. N2 - We evaluated the ability of one-month follow-up contrast-enhanced ultrasound (CEUS) with second-generationcontrast agent in monitoring radio frequencyablation (RFA) and transcatheter arterial chemoembolization(TACE) treatments of hepatocellular carcinoma(HCC). One-hundred forty-eight HCCs were studiedusing CEUS: 110 nodules were treated with RFA [41/110RFA were performed using a pretreatment and animmediate postablation evaluation using CEUS (group1); 69/110 using only US guidance (group 2)] and 38nodules treated with TACE. For statistical analysis,McNemar test was used. Overall complete response wasobserved in 107/148 nodules (92/110 treated with RFAand 15/38 with TACE). A better rate of ...
Background. Transarterial chemoembolization alone or in association with radiofrequency ablation is an effective bridging strategy for patients with hepatocellular carcinoma awaiting for a liver transplant.However, cost of this therapymay limit its utilization. This study was designed to evaluate the outcomes of a protocol involving transarterial embolization, percutaneous ethanol injection, or both methods for bridging hepatocellular carcinomas prior to liver transplantation. Methods. Retrospective review of all consecutive adult patients who underwent a first liver transplant as a treatment to hepatitis C-related hepatocellular carcinoma at our institution between 2002 and 2012. Primary endpoint was patient survival. Secondary endpoint was complete tumor necrosis. Results. Forty patients were analyzed, age 58 ± 7 years.There were 23 males (57.5%). Thirty-six (90%) out of the total 40 patients were within Milan criteria. Complete necrosis was achieved in 19 patients (47.5%). One-, 3-, and ...
TY - JOUR. T1 - An overview of loco-regional treatments in patients and mouse models for hepatocellular carcinoma. AU - Bimonte, Sabrina. AU - Barbieri, Antonio. AU - Palaia, Raffaele. AU - Leongito, Maddalena. AU - Albino, Vittorio. AU - Piccirillo, Mauro. AU - Arra, Claudio. AU - Izzo, Francesco. PY - 2015/3/9. Y1 - 2015/3/9. N2 - Hepatocellular carcinoma is a highly aggressive malignancy and is the third leading cause of cancer-related deaths worldwide. Although surgery is currently considered the most effective curative treatment for this type of cancer, it is note that most of patients have a poor prognosis due to chemioresistence and tumor recurrence. Loco-regional therapies, including radiofrequency ablation, surgical resection and transcatheter arterial chemoembolization play a major role in the clinical management of hepatocellular carcinoma. In order to improve the treatment outcome of patients diagnosed with this disease, several in vivo studies by using different techniques on cancer ...
Hepatocellular carcinoma is considered to be the fifth most common cancer worldwide. Resection and liver transplantation have a high survival in the correct clinical scenarios; however, locoregional therapy has many advantages over tumor resection like preservation of hepatic parenchyma and overall less morbidity and mortality. Our aim was to present the role of dynamic subtraction MRI technique in the assessment of treatment response of hepatocellular carcinoma to transarterial chemoembolization. The study consisted of 43 patients with 55 hepatocellular carcinoma lesions who underwent transarterial chemoembolization procedure and followed up by dynamic MRI of the liver with post processing to obtain subtraction images 1-1.5 months after the procedure. If no signs of disease activity, another follow up study was preformed 2-4 months later. Five patients were excluded due to misregistration artifact at the subtraction images. The final cohort is 38 patients having 50 lesions. Precontrast T1, T2, dynamic
Abdel-Rahman O, Elsayed Z. Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No.: CD013431. DOI: 10.1002/14651858. ...
TY - JOUR. T1 - Liver transplantation after radioembolization in a patient with unresectable HCC. AU - Luna, Laura E.Moreno. AU - Kwo, Paul Y.. AU - Roberts, Lewis R.. AU - Mettler, Teresa A.. AU - Gansen, Denise N.. AU - Andrews, James C.. AU - Wiseman, Gregory A.. AU - Misra, Vijay Laxmi. PY - 2009/11/16. Y1 - 2009/11/16. N2 - Background. A 58-year-old white man who was being followed by his hepatologist for nonalcoholic steatohepatitis-related liver cirrhosis and portal hypertension and who had been found to have a biopsy-proven hepatocellular carcinoma (HCC) on routine screening, self-referred to our center for a second opinion on the management of his HCC. Investigations. Laboratory investigations, CT scan of the abdomen and chest, bone scan and technetium macroaggregated albumin scan. Diagnosis. The patient had unresectable HCC. Management. The patient underwent two treatments with Yttrium-90 glass microspheres, which were performed as outpatient procedures 1 month and 3 months after ...
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
Transcatheter arterial chemoembolization (TACE) offers a survival benefit to patients with intermediate hepatocellular carcinoma (HCC). A widely accepted TACE regimen includes administration of doxoru
Objective: Hepatocellular carcinoma with portal vein thrombosis is considered a relative contraindication for transarterial chemoembolization (TACE). The aim of our study was to evaluate the prognostic factors and management in patients with hepatocellular carcinoma with portal vein thrombosis (PVT). Methods: Between February 2011 and February 2015, 140 patients presented to our specialized multidisciplinary HCC clinic. All were assessed by imaging at regular intervals for tumor response and the data compared with baseline laboratory and imaging characteristics obtained before treatment. Results: At the end of the follow up in February 2015, 78 (55.7%) of the 140 patients had died, 33.1% in the 1st year and 20.7% in the 2nd year. The overall median survival was 10 months from the date of diagnosis. Clinical progression was noted in 45 (32.1%). Univariate analysis revealed that, the Child-Pugh score, the performance states (Eastern Cooperative Oncology Group ECOG 0-1) and the presence of ascites
Introduction: Primary hepatic neuroendocrine carcinoma (PHNEC) is an extremely rare neuroendocrine carcinoma (NEC) that originate from the liver. The diagnosis of PHNEC remains challenging because of its rarity, and its lack of unique clinical features. Available treatment options for PHNEC include surgical resection of the liver tumor(s), radiotherapy, liver transplant, transcatheter arterial chemoembolization (TACE), and administration of somatostatin analogues ...
Introduction: Primary hepatic neuroendocrine carcinoma (PHNEC) is an extremely rare neuroendocrine carcinoma (NEC) that originate from the liver. The diagnosis of PHNEC remains challenging because of its rarity, and its lack of unique clinical features. Available treatment options for PHNEC include surgical resection of the liver tumor(s), radiotherapy, liver transplant, transcatheter arterial chemoembolization (TACE), and administration of somatostatin analogues ...
The significance of this study relates to the lack of availability of a number of drugs that have been used for chemoembolization over the last several years, including ethiodol, powdered cisplatin, and powdered doxorubicin. Ethiodol is and will be available in the future. However, powdered doxorubicin has been on and off the market and powdered cisplatin has been unavailable for several years. Based on our findings, chemoembolization of hepatocellular carcinoma with CAM performed similarly to drug-eluting beads, both in regards to treatment response and disease control. These benchmarks directly correlate to survival and can improve the opportunity for patients to undergo liver transplantation, which is the best opportunity for cure. Given the lack of availability of powdered cisplatin in the United States, we would recommend drug-eluting beads over adriamycin based on these results if these are the only two options available to an interventional oncologist. Other findings of note included a ...
TY - JOUR. T1 - Loco-regional interventional treatment of hepatocellular carcinoma. T2 - Techniques, outcomes, and future prospects. AU - Lencioni, Riccardo. AU - Crocetti, Laura. AU - De Simone, Paolo. AU - Filipponi, Franco. PY - 2010. Y1 - 2010. N2 - Summary Loco-regional interventional treatments continue to evolve and to play a major role in the therapeutic management of hepatocellular carcinoma (HCC). Image-guided ablation is established as the treatment of choice for patients with early-stage HCC when transplantation or resection is precluded. Recent refinements in technique have substantially increased the ability of radiofrequency ablation to achieve sustained complete response of target tumors in properly selected patients, and new alternate thermal and nonthermal methods for local tumor treatment are currently under investigation. Transarterial chemoembolization (TACE) is the standard of care for patients with multinodular disease at the intermediate stage. The introduction of ...
The diagnosis and treatment of hepatocellular carcinoma (HCC) have witnessed major changes over the past decade. Until the early 1990s, HCC was a relatively rare malignancy, typically diagnosed at an advanced stage in a symptomatic patient, and there were no known effective palliative or therapeutic options. However, the rising incidence of HCC in several regions around the world coupled with emerging evidence for efficacy of screening in high-risk patients, liver transplantation as a curative option in select patients, ability to make definitive diagnosis using high-resolution imaging of the liver, less dependency on obtaining tissue diagnosis, and proven efficacy of transarterial chemoembolization and sorafenib as palliative therapy have improved the outlook for HCC patients. In this article, we present a summary of the most recent information on screening, diagnosis, staging, and different treatment modalities of HCC, as well as our recommended management approach.
Find Interventional Radiologists that treat Drug-Eluting Bead Therapy, See Reviews and Book Online Instantly. Its free! All appointment times are guaranteed by our dentists and doctors.
Experimental Design: Thirty-two VX2 tumor-bearing New Zealand white rabbits underwent longitudinal imaging on clinical 3T-MRI and CT scanners before and up to 2 weeks after complete conventional transarterial chemoembolization (cTACE) using ethiodized oil (lipiodol) and doxorubicin. MR-spectroscopic imaging (MRSI) was employed for pHe mapping. Multiparametric MRI and CT were performed to quantify tumor enhancement, diffusion, and lipiodol coverage of the tumor posttherapy. In addition, incomplete cTACE with reduced chemoembolic doses was applied to mimic undertreatment and exploit pHe mapping to detect viable tumor residuals. Imaging findings were correlated with histopathologic markers indicative of metabolic state (HIF-1α, GLUT-1, and LAMP-2) and viability (proliferating cell nuclear antigen and terminal deoxynucleotidyl-transferase dUTP nick-end labeling). ...
Surgery, ablation therapy or transarterial chemoembolization (TACE) may be offered for stage A liver cancer. Learn about treatment and options.
Inclusion Criteria: Stage 1 - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 within 7 days prior to randomization - Locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of - Liver Diseases criteria in cirrhotic patients - Child-Pugh class A within 7 days prior to randomization - Disease that is not amenable to curative surgical and/or locoregional therapies - No prior systemic treatment for HCC - Life expectancy ,= 3 months - Availability of a representative tumor specimen that is suitable for determination of PD-L1 and/or additional biomarker status via central testing Stage 1 and Stage 2 - Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 - Adequate hematologic and end-organ function within 7 days prior to initiation of study treatment - Documented virology status of hepatitis, as confirmed by screening tests for ...
A clinical case of the treatment of a patient with metastatic inoperable liver cancers with the use of radiofrequency ablation combined with regional chemotherapy and chemoembolization
Updated 3 Dec 2013 Im in Frankfurt on a business trip and thanks to Peter, managed to steal some time to visit a German cancer clinic. The clinic is PraxisKlinik Siebenhuner and is on the outskirts of Frankfurt. Peter uses it for hyperthermia after a trans-arterial chemoembolisation session with Vogl. Its about a 30-minute taxi journey…
RADIOLOGY: HEPATOBILIARY: Case# 34577: CIRRHOSIS WITH SPLENOMEGALY AND ASCITES. This patient reportedly has had chemoembolization of a left lobe hepatocellular carcinoma. He now presents in encephalopathy. - 00137365.jpg
Chemotherapy. These are medicines that kill cancer cells. They may be given before or after surgery. They are delivered into a vein (IV) or by shot (injection), or by mouth (oral). The medicines may also be delivered to the liver. This is done with a tube (catheter) into the livers main artery. This is called chemoembolization of hepatic artery. The medicine is mixed with a substance that blocks the flow of blood to the tumor. This causes problems with the tumors growth ...
In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Umberto Ricardi discusses the use of loco-regional therapy to treat brain metastases. Earn CME Credit for a related activity: © 2017 Imedex, LLC. organizing Cancer Therapy Conferences in 2019 in USA, Europe, Australia and Other Prominent locations across the globe. We organize Cancer Therapy Meetings in the fields related to Cancer Therapy like Oncology, Chemotherapy, Palliative Therapy and Radiation Therapy.
Hepatic artery chemoembolization (HACE), sometimes called transarterial chemoembolization (TACE), combines hepatic artery ... Hepatic artery embolization , also known as trans-arterial embolization (TAE), is one of the several therapeutic methods to ... Arterial Chemotherapy Infusion of the Liver (and) Chemoembolization of the Liver (TACE)[3]). Leal, Julie N; Kingham, T. Peter ( ... The role of surgery and chemoembolization in the management of carcinoid. California Carcinoid Fighters Conference. October 25 ...
Currently, therapeutic doses of radiation can be targeted to tumors with great accuracy using linear accelerators in radiation ... When comparing SIRT with transarterial chemoembolization (TACE), several studies have shown favorable results for SIRT, such as ... The intention was to develop a microsphere that would have a similar therapeutic radiation dose to yttrium-90, but would have ... Targeted alpha-particle therapy Transcatheter arterial chemoembolization Cromheecke, M.; Konings, A. W.; Szabo, B. G.; Hoekstra ...
Hepatic artery chemoembolization (HACE), sometimes called transarterial chemoembolization (TACE), combines hepatic artery ... Carcinoid Tumors and the Carcinoid Syndrome: What's New in the Therapeutic Pipeline. (The Carcinoid Cancer Foundation: ... Arterial Chemotherapy Infusion of the Liver (and) Chemoembolization of the Liver (TACE) Archived 2014-12-24 at ... The role of surgery and chemoembolization in the management of carcinoid. California Carcinoid Fighters Conference. October 25 ...
Ablative Chemoembolization: Combined injection of chemotherapy and embolic agents into the arterial blood supply of a tumor, ... By contrast, therapeutic IR procedures provide direct treatment-they include catheter-based medicine delivery, medical device ... In addition, the interventional radiologist has an array of both therapeutic and palliative interventions to offer the patient ... IR performs both diagnostic and therapeutic procedures through very small incisions or body orifices. Diagnostic IR procedures ...
... chemoembolization, therapeutic MeSH E02.565.280.853 - short-wave therapy MeSH E02.565.280.945 - ultrasonic therapy MeSH E02.565 ... therapeutic touch MeSH E02.190.901.968 - witchcraft MeSH E02.190.901.984 - yoga MeSH E02.218.085.090 - body piercing MeSH ... therapeutic touch MeSH E02.190.525.937 - yoga MeSH E02.190.599.186 - kinesiology, applied MeSH E02.190.599.233 - manipulation, ...
When it bears a chemotherapy drug, the process is called chemoembolization. Transcatheter arterial chemoembolization (TACE) is ... "Therapeutic percutaneous embolization for extra-axial vascular lesions of the head, neck, and spine." J Neurosurg. 1975 Sep;43( ... therapeutic), as a hemostatic treatment for bleeding or as a treatment for some types of cancer by deliberately blocking blood ... Treated either by particle infarction or transcatheter arterial chemoembolization (TACE). Uterine fibroids Arteriovenous ...
Diagnostic and Therapeutic *Interventional radiology is concerned with using expert imaging of the human body, usually via CT, ... transarterial chemoembolization) ... Diagnostic (D) or therapeutic (T) specialty. Surgical (S) or ... A further subdivision is the diagnostic versus therapeutic specialties. While the diagnostic process is of great importance in ...
... as is done in peptide receptor radionuclide therapy for neuroendocrine tumors and in chemoembolization or radioactive ... a drug or other therapeutic agent with a narrow therapeutic range (i.e. having little difference between toxic and therapeutic ... The therapeutic index (TI; also referred to as therapeutic ratio) is a quantitative measurement of the relative safety of a ... The effective therapeutic index can be affected by targeting, in which the therapeutic agent is concentrated in its area of ...
Recently,[when?] there has been an increasing interest in the use of Lipiodol as a therapeutic agent in the management of ... It is used in chemoembolization applications as a contrast agent in follow-up imaging. Lipiodol is also used in ... computed tomography in the management of hepatocellular carcinoma with transcatheter arterial chemoembolization". Journal of ...
Drug eluting bead chemoembolization (DEB-TACE): delivery of microparticles that are themselves loaded with the chemotherapy ... Therapeutic interventional oncology procedures may be classified further into ablation techniques that destroy neoplastic ... Salem, Riad; Lewandowski, Robert J. (June 2013). "Chemoembolization and radioembolization for hepatocellular carcinoma". ... First therapeutic embolization procedure (of a carotid-cavernous fistula); described by Brooks. 1960s - Radioisotopes such as ...
Monitoring TACE therapeutic results by contrast imaging techniques is performed as for ablative therapies initially after one ... Transarterial chemoembolization (TACE) is part of palliative therapies for HCC used in intermediate stages of the disease. It ... On the other hand, CE-CT is also limited by the presence of Lipiodol (iodine oil), therefore the evaluation of therapeutic ... CEUS also allows assessment of therapeutic effect immediately post-procedure (with the possibility of reintervention in case of ...
When it bears a chemotherapy drug, the process is called chemoembolization. Transcatheter arterial chemoembolization (TACE) is ... therapeutic), as a hemostatic treatment for bleeding or as a treatment for some types of cancer by deliberately blocking blood ... Treated either by particle infarction or transcatheter arterial chemoembolization (TACE). ...
A liver support system is a therapeutic device to assist in performing the functions of the liver in persons with liver damage ... Liver Resection in hepatocellular carcinoma Transarterial Chemoembolization (TACE) Partial resection in living donor ... Pathophysiological basis of therapeutic options". Blood Purif. 20 (3): 252-261. doi:10.1159/000047017. PMID 11867872. Stravitz ... Therapeutic Apheresis and Dialysis. 13 (6): 549-55. doi:10.1111/j.1744-9987.2009.00708.x. PMID 19954480. Steiner, C; Mitzner, S ...
"Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma". ClinicalTrials. ... biomarkers and therapeutic targets". Journal of Hepatology. 67 (3): 603-618. doi:10.1016/j.jhep.2017.04.009. ISSN 1600-0641. ... chemoembolization or radioembolization).[citation needed] Surgical removal of the tumor is associated with better cancer ... "Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable ...
K J Stelzer (2000). "Acute and long-term complications of therapeutic radiation for skull base tumors". Neurosurg Clin N Am. 11 ... "Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma". ClinicalTrials. ... An increasing amount of data has shown that proton therapy has great potential to increase therapeutic tolerance for patients ... compared to therapeutic megavoltage (MeV) photon beams (~60%). X-ray radiation dose falls off gradually, unnecessarily damaging ...
The therapeutic outcomes are improving due to the combined approach such as spreading the treatment target to non-bronchial ... Seki, Akihiko; Shimono, Chigusa (September 2017). "Transarterial chemoembolization for management of hemoptysis: initial ... and the evolution of therapeutic strategies. BAE has become the gold standard for hemoptysis for its dramatic improvement. ...
Fogarty S (March 2018). "Fertility Massage: an Unethical Practice?". International Journal of Therapeutic Massage & Bodywork. ... uterine arterial embolization or uterine arterial chemoembolization). The United States uses a multi dose protocol of ...
CKI, combined with transarterial chemoembolization (TACE), is believed to increase the therapeutic efficacy of unresectable ... is believed to increase the therapeutic efficacy of unresectable hepatocellular carcinoma (HCC). We report an updated and ... Transarterial chemoembolization is one of the few effective therapeutic treatments for unresectable HCC. However, TACE only has ... The Therapeutic Efficacy and Safety of Compound Kushen Injection Combined with Transarterial Chemoembolization in Unresectable ...
... spectral imaging in evaluating the effect of transarterial chemoembolization (TACE).The records of 67 patients with ... Spectral CT in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma: A ... Spectral CT with quantitative analysis of AP NIC may help to evaluate the utility and predict the therapeutic effect of TACE. ... spectral imaging in evaluating the effect of transarterial chemoembolization (TACE).The records of 67 patients with ...
... and the therapeutic results obtained in those patients was evaluated. Seg-Lp-CT was classified into four types (type I, ... Nishimine, K., Uchida, H., Matsuo, N. et al. Segmental transarterial chemoembolization with lipiodol mixed with anticancer ... Segmental transarterial chemoembolization with lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma ... Uchida H, Ohishi H, Matsuo N, Sakaguchi H, Yoshioka T, Sato O, Yoshimura H (1989) Transcatheter arterial chemoembolization ...
Chemoembolization, Therapeutic * Chitin / administration & dosage * Chitin / analogs & derivatives* * Chitin / chemistry * ... 5-fluorouracil loaded chitosan microspheres for chemoembolization J Microencapsul. Nov-Dec 1999;16(6):741-9. doi: 10.1080/ ... 5-Fluorouracil was incorporated in the matrix for the possible use of the microspheres in chemoembolization. The size and size ...
... Gan To Kagaku Ryoho. 1989 Oct;16(10):3423-8. ... Hydroxyapatites / therapeutic use* * Injections, Intra-Arterial * Iodized Oil / administration & dosage * Iodized Oil / ... The purpose of this study was to elucidate the availability of hydroxyapatite (HAp) granules as a chemoembolic agent in chemo embolization ...
... and patient survival after the treatment of pulmonary metastases using transpulmonary chemoembolization (TPCE) in palliative... ... Therapeutic chemoembolization Lung neoplasms Interventional radiology Palliative care Neoadjuvant therapy Abbreviations. Angio- ... Schneider P, Kampfer S, Loddenkemper C, Foitzik T, Buhr HJ (2002) Chemoembolization of the lung improves tumor control in a rat ... Pohlen U, Rieger H, Meyer BT et al (2007) Chemoembolization of lung metastases--pharmacokinetic behaviour of carboplatin in a ...
... follow-up CT and therapeutic results.. Nishimine K1, Uchida H, Matsuo N, Sakaguchi H, Hirohashi S, Nishimura Y, Guo Q, Ohishi H ... Segmental transarterial chemoembolization with Lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma ... We developed segmental Lp-TAE, which is transcatheter hepatic sub-subsegmental, subsegmental, or segmental chemoembolization ... and the therapeutic results obtained in those patients was evaluated. Seg-Lp-CT was classified into four types (type I, ...
Computed Tomographic Perfusion Imaging for the Therapeutic Response of Chemoembolization for Hepatocellular Carcinoma. Yang, ...
Other therapeutic approaches include:. *Hepatic artery embolization with chemotherapy (chemoembolization).. *Alcohol ablation ... Hepatic artery embolization with chemotherapy (chemoembolization).. *Alcohol ablation via ultrasound-guided percutaneous ... therapeutic touch, massage therapy and guided imagery have no side effects and have been reported to enhance well-being. ... therapeutic touch, massage therapy and guided imagery have no side effects and have been reported to enhance well-being. ...
Therapeutic options include:. *resection of metastatic nodules. *hepatic intra-arterial chemotherapy. *intra-arterial hepatic ... chemoembolization. *immunoembolization. *systemic chemotherapy. *targeted therapy (i.e. monoclonal antibodies). *immunotherapy ...
... the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. ... Dive into the research topics of GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular ... carcinoma treated with transcatheter arterial chemoembolization. Together they form a unique fingerprint. ...
Therapeutic effect of transarterial chemoembolization using cisplatin-lipiodol mixture in Therapeutic effect of transarterial ... chemoembolization using cisplatin-lipiodol mixture in hepatocelluar carcinoma / 대한암학회지 Mi-Sun KIM; Ki-Bum CHO; Moo-In PARK; In- ...
Therapeutic effect of transcatheter arterial chemoembolization combined with iodine-125 se Therapeutic effect of transcatheter ... Objective To study the efficacy of combined transcatheter arterial chemoembolization(TACE)with iodine-125 seed implantation in ... arterial chemoembolization combined with iodine-125 seed strand implantation for treating hepatocellular carcinoma with portal ...
Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular ... Keywords: carcinoma, hepatocellular, chemoembolization, therapeutic, microspheres, arteriovenous fistula. This work is ... Objective: To evaluate the feasibility and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) in ... Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular ...
To compare the efficacy and safety between conventional transarterial chemoembolization (cTACE) and drug-eluting beads TACE ( ... Predictors of therapeutic effect of transarterial chemoembolisation using drug-eluting beads for hepatocellular carcinoma. Clin ... The chemoembolization was performed as selectively as possible. Lobar chemoembolization was performed only if the tumor feeding ... Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of ...
Herein, we review the molecular biology of circRNAs in HBV-HCC and their potential in therapeutic strategies. ... Herein, we review the molecular biology of circRNAs in HBV-HCC and their potential in therapeutic strategies. ... prognostic and therapeutic purposes. So far, at least four circRNA/miRNA regulatory axes such as circRNA_101764/miR-181, ... prognostic and therapeutic purposes. So far, at least four circRNA/miRNA regulatory axes such as circRNA_101764/miR-181, ...
Chemoembolization, Therapeutic. Administration of antineoplastic agents together with an embolizing vehicle. This allows slow ...
Therapeutic Approaches; Radiofrequency Ablation; Chemoembolization; Surgical Management of Intrahepatic Biliary Tract Cancer; ... Finally, the full arsenal of therapeutic approaches is presented, from the local to systemic, established to experimental. ...
Therapeutic Approaches; Radiofrequency Ablation; Chemoembolization; Surgical Management of Intrahepatic Biliary Tract Cancer; ... Finally, the full arsenal of therapeutic approaches is presented, from the local to systemic, established to experimental. ...
Pain Palliation Treatment: Therapeutic options consisting of ablation, chemoembolization or radioembolization designed ... Chemoembolization: Selective delivery of chemotherapy directly to the tumor through a catheter located in the artery feeding ... In addition, Interventional Oncology provides a range of therapeutic options used for palliative care including biopsy, ...
2016) Hepatic Resection or Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. ... Intravoxel Incoherent Motion Diffusion Weighted Imaging for the Therapeutic Response of Transarterial Chemoembolization for ... This review summarized seven potential treatment regimes which including transarterial chemoembolization (TACE), TACE combined ... Hepatocellular Carcinoma: Review of Current Treatment with a Focus on Transarterial Chemoembolization and Radiofrequency ...
S. Dhar, A. Kumar, L. Zhang et al., "Dietary pterostilbene is a novel MTA1-targeted chemopreventive and therapeutic agent in ... Metastasis-Associated Protein 1 Is Involved in Angiogenesis after Transarterial Chemoembolization Treatment. Tao Xue,1,2 ... Background. Transarterial chemoembolization (TACE), a well-established treatment for unresectable hepatocellular carcinoma (HCC ... C. Lo, H. Ngan, W. Tso et al., "Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable ...
therapeutic protocol • PAIN RECURRENCE 397 cases (after local treatment) • INITIAL TREATMENT 585 cases - vert 191 cases - vert ... LOCAL TT for BONE METASTASES K SURGERY CHEMOEMBOLIZATION RTH CEMENTOPLASTY Local TT for Bone Metastase ... local recurrence 37V THERAPEUTIC PROTOCOL • VERT 92 • VERT + RTH 6 • VERT + SURG 6 ... Initial treatment of vertebral metastases • point of therapeutic decision - radio / chemo sensitivity - spine instability • ...
This study investigates the efficacy of MLT on tumor therapeutic strategies by meta-analysis.Methods: After searching several ... Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis Yi Wang,* Pengcheng Wang,* Xiaoli ... transcatheter artery chemoembolization; T, treatment group; C, control group; ER, estrogen receptor; IL-2, interleukin 2. ... Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis. ...
Cancer Chemoembolization (Therapeutic Chemoembolization) * Vertebroplasty (Kyphoplasty) Board Certifications. See the board ...
Cancer Chemoembolization (Therapeutic Chemoembolization) * Cryosurgery * Biliary Tract Diseases * Ultrasound * Angioplasty * ...
... Transarterial chemoembolization (TACE) based on drug-eluting beads (DEB-TACE) is widely used for ... Transarterial chemoembolization (TACE) based on drug-eluting beads (DEB-TACE) is widely used for unresectable hepatocellular ... This study aimed to perform a network meta-analysis to evaluate the therapeutic effect and safety of various modalities in ... Transcatheter arterial chemoembolization (TACE) is recognized as one of the most commonly used modalities for non-surgical ...
Chemoembolization, Therapeutic. *Diagnostic Imaging. *Liver Neoplasms. *Practice Guidelines As Topic. *Radioembolization. * ...
Key words: Arteriovenous fistula; Carcinoma, hepatocellular; Chemoembolization, therapeutic. View this abstract indexed in ...
Newer therapeutic strategies have included chemoembolization, intra-arterial chemotherapy, and intraoperative cryotherapy. ... is an option for benign lesions that have resulted in significant organ compromise with no other effective therapeutic modality ...
  • CKI, combined with transarterial chemoembolization (TACE), is believed to increase the therapeutic efficacy of unresectable hepatocellular carcinoma (HCC). (
  • This study aimed to investigate the value of computed tomographic (CT) spectral imaging in evaluating the effect of transarterial chemoembolization (TACE). (
  • Spectral CT with quantitative analysis of AP NIC may help to evaluate the utility and predict the therapeutic effect of TACE. (
  • To evaluate the feasibility and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) in patients with hepatocellular carcinoma (HCC) and arterioportal shunts (APSs). (
  • Objective To study the efficacy of combined transcatheter arterial chemoembolization(TACE)with iodine -125 seed implantation in treating hepatocellular carcinoma (HCC)with portal vein tumor thrombus (PVTT). (
  • To compare the efficacy and safety between conventional transarterial chemoembolization (cTACE) and drug-eluting beads TACE (DEB-TACE) in patients with infiltrative hepatocellular carcinoma (iHCC). (
  • This review summarized seven potential treatment regimes which including transarterial chemoembolization (TACE), TACE combined with sorafenib, TACE combined with radiotherapy (RT), hepatectomy, hepatic arterial infusion chemotherapy (HAIC), HAIC combined with sorafenib and HAIC combined with RT in the treatment of HCC with PVTT. (
  • Transarterial chemoembolization (TACE), a well-established treatment for unresectable hepatocellular carcinoma (HCC), blocks the arterial blood supply to the tumor, which can be short-lived as development of collateral neovessels, leading to the failure of treatment. (
  • our results shed light on better understanding in neovascularization, which are helpful to predict prognosis of TACE, and provide evidences for intervention to improve therapeutic effects on HCC. (
  • Therefore, transcatheter arterial chemoembolization (TACE), targeting necrosis and shrinkage of liver tumors, has been considered to be a promising treatment for HCC patients who are not suitable for surgical operation. (
  • The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody compared with transarterial chemoembolization (TACE) for patients with intermedia. (
  • The purpose is to investigate both the efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib versus TACE alone. (
  • To discuss postoperative thrombocytopenia in the treatment of hepatocellular carcinoma (HCC) through transcatheter arterial chemoembolization (TACE) with single application of Lobaplatin as chemothera. (
  • Hepatic artery chemoembolization (HACE), sometimes called transarterial chemoembolization (TACE), combines hepatic artery embolization with hepatic artery chemo infusion. (
  • To introduce an animal model of hepatocellular carcinoma (HCC) in ACI-rats, and to evaluate the therapeutic effects of Poly-lactide-co-glycolide(Plcg)-microspheres in the transarterial chemoembolization (TACE) in this model, as well the value of this model in the experiments of interventional therapy. (
  • To compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) to transarterial chemoembolization/embolization (TACE/TAE) for the treatment of advanced hepatocellular carcinoma (HCC) with major portal vein tumor thrombosis (PVTT). (
  • We compared the efficacy of transcatheter arterial chemoembolization (TACE) in combination with CT-guided radiofrequency ablation (RFA) with that of surgical resection (SR) in patients with hepatocellular carcinoma (HCC) within the up-to-seven criteria. (
  • This study aimed to evaluate the therapeutic efficacy and safety of repeated transarterial chemoembolization (TACE) with additional radiation therapy (RT) in hepatocellular carcinoma (HCC) with portal vein (PV) invasion. (
  • Transarterial chemoembolization (TACE) is the major modality utilized for tumor downstaging for transplant and for local therapy in non-transplant patients. (
  • The current study is designed to assess the potential therapeutic benefit of adding TH-302 to the standard doxorubicin based TACE regimen in patients with advanced hepatocellular carcinomas. (
  • The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE). (
  • However, few studies have addressed the use of IVIM-DWI for the evaluation of transarterial chemoembolization (TACE) response in hepatocellular carcinoma (HCC) patients. (
  • Objectives: The purpose of the present study was to explore the role of IVIM-DWI for the therapeutic response of TACE for HCC. (
  • Conclusions: IVIM-DWI parameters can be used as potential markers for the therapeutic response of TACE for HCC. (
  • To evaluate the role and limitation of fast multiplanar spoiled gradient-recalled (FMPSPGR) MR dynamic contrast scanning in the follow-up of patients with HCC treated by transarterial chemoembolization (TACE). (
  • The common therapeutic regimens of HCC include surgical resection, chemotherapy (e.g., sorafenib), interventional chemotherapy [e.g., transcatheter arterial chemoembolization (TACE)], and radiation. (
  • Trans-arterial chemoembolization (TACE), radiotherapy and chemotherapy are the current treatment modalities for HCC, and sorafenib is the only drug that has been approved by the FDA 7 . (
  • CKI combined with TACE treatment could elevate the therapeutic efficacy of unresectable HCC 9 . (
  • The aim of this study is to analyze the therapeutic effect of adjuvant TACE after resection.Patients receiving curative resection (R0) were randomized to postoperative TACE group and no TACE group. (
  • So to reduce the recurrence rate of HCC, some interventions had been tried in clinic, including transarterial chemoembolization (TACE), immunotherapy, and interferon treatment etc. (
  • Unresectable HCC are treated with locoregional therapies involving transarterial chemoembolization (TACE), percutaneous ethanol injection, or radiofrequency ablation ( 11 ). (
  • TACE represents an intraarterial administration of therapeutic drugs combined with embolizing agents which leads to a more selective distribution and a higher retention time of therapeutics within HCC. (
  • Transcatheter arterial chemoembolization (TACE) has become the mainstay of treatment for unresectable HCC. (
  • We treated twelve patients with HCC by PTPCE in combination with transcatheter arterial chemoembolization (TACE). (
  • PTPCE in combination with TACE has exellent therapeutic effects not only for main tumor but also for portal or capsular invasion. (
  • The chemotherapeutic analogue (combining chemotherapy with embolization) is called chemoembolization, of which transcatheter arterial chemoembolization (TACE) is the usual form. (
  • The objectives of this retrospective study was to evaluate the efficacy of stereotactic body radiation therapy (SBRT) for small non-resectable hepatocellular carcinoma (HCC) and SBRT combined with transarterial chemoembolization (TACE) for advanced HCC with portal vein tumor thrombosis (PVTT). (
  • Many modalities such as surgical resection, percutaneous ethanol injection (PEI), radiofrequency ablation (RFA), Y90 microspheres, external radiation therapy (RT) and transarterial chemoembolization (TACE) have been tried in the treatment for HCC [ 3 - 8 ], but the optimal treatment approach remains controversial. (
  • Transcatheter arterial chemo-embolization (TACE) is a therapeutic procedure to treat primary and metastatic liver cancer. (
  • Transarterial chemoembolization (TACE) or sorafenib is recommended for hepatocellular carcinoma BCLC stages B and C respectively. (
  • Background/Aims: Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but there is much controversy about TACE refractoriness. (
  • During early stage HCC, therapeutic options include liver transplantation, resection of the tumor, or transarterial chemoembolization (TACE). (
  • As we previously reported LDH is an important predictive factor in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE). (
  • However, since the therapeutic efficacy of HAIC is lower than that of the aforementioned therapies, it is generally used in cases of advanced HCC in which excision, RFA and TACE cannot be performed or in cases where no therapeutic efficacy is expected, as well as in multiple tumor cases that demonstrate resistance to TACE. (
  • Beneath surgical resection, local ablative (e.g., radiofrequency ablation - RFA, microwave ablation - MWA) and loco-regional (e.g., transarterial chemoembolization - TACE) treatments are favored for early to intermediate stage of HCC. (
  • Balloon-occluded transcatheter arterial chemoembolization (B-TACE) using a microballoon catheter was performed to administer miriplatin, and the early therapeutic efficacy and safety of the procedure were evaluated. (
  • Although the diffusion of surveillance programs of cirrhotic patients has led to an increased detection of HCC at an early stage, most patients are diagnosed at intermediate-advanced stages, when the only proven options available to improve survival are transarterial chemoembolization (TACE) and molecularly targeted therapy with the multikinase inhibitor, Sorafenib. (
  • In particular, TACE is an effective treatment increasing the survival rate of selected patients with intermediate stage HCC, and to improve its efficacy, new therapeutic approaches with enhanced antitumoral effect and reduced toxicity, such as doxorubicin-drug eluiting beads and radiating agents, have been investigated. (
  • A total of 98 patients with nonresectable hepatocellular carcinoma (HCC) undergoing segmental Lp-TAE (Seg-Lp-TAE) were studied, and the relationship between the CT pattern observed after Seg-Lp-TAE (Seg-Lp-CT) and the therapeutic results obtained in those patients was evaluated. (
  • 2016) Hepatic Resection or Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. (
  • This study aimed to perform a network meta-analysis to evaluate the therapeutic effect and safety of various modalities in treating advanced hepatocellular carcinoma (HCC). (
  • Pancreas lipiodol embolism induced acute necrotizing pancreatitis following transcatheter arterial chemoembolization for hepatocellular carcinoma: A case report and literature review. (
  • Qian J, Truebenbach J, Graepler F, Pereira P, Huppert P, Eul T, Wiemann G, Claussen C. Application of poly-lactide-co-glycolide-microspheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma. (
  • Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. (
  • Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis. (
  • To report technical success, safety profile and oncological results of balloon-occluded transcatheter arterial chemoembolization using a balloon micro-catheter and epirubicin-loaded polyethylene-glycol (PEG) microsphere (100 ± 25 µm and 200 ± 50 µm) in patients with hepatocellular carcinoma (HCC). (
  • The rising incidence of liver cancer has also placed radiofrequency ablation and chemoembolization of liver lesions at the forefront of interventional therapies for hepatocellular carcinoma. (
  • The incidence of hepatocellular carcinoma is increasing in the western world, and this type of carcinoma often represents a therapeutic challenge. (
  • We developed cisplatin suspended in lipiodol (CSL)-fibrin adhesive mixture as a new embolic material in arterial and portal chemoembolization therapy for unresectable hepatocellular carcinoma (HCC). (
  • Publications] TORU BEPPU: 'A new chemoembolization therapy for unresectable hepatocellular carcinoma using Aclarubicin microspheres in combination with Cisplatin suspended in lipiodol. (
  • Neutrophil-lymphocyte ratio predicts the therapeutic benefit of neoadjuvant transarterial chemoembolization in patients with resectable hepatocellular carcinoma. (
  • Hepatocellular carcinoma is the second most deadly cancer type globally, requiring the development of alternative or complementary therapeutic and prophylactic methods. (
  • Therapeutic progress in established hepatocellular carcinoma has largely been restricted to locoregional interventions. (
  • We developed segmental Lp-TAE, which is transcatheter hepatic sub-subsegmental, subsegmental, or segmental chemoembolization using Lipiodol introduced into the tumor-bearing hepatic sub-subsegment, subsegment, or segment as the target area. (
  • Transcatheter arterial chemoembolization is intended to deliver a highly concentrated dose of chemotherapy to tumor cells, prolong the contact time between the chemotherapeutic agents and the cancer cells, and minimize systemic toxicity. (
  • Transcatheter arterial embolization without chemotherapy (TAE or bland embolization) has often been mistakenly categorized as a form of chemoembolization. (
  • Publications] Satoshi Ikei: 'Changes in Interleukin 6,Interleukin 8,C-reactive protein and Panceatic Secretory Trypsin Inhibitor after Transcatheter Arterial Chemoembolization' CYTOKINE. (
  • Transcatheter chemoembolization is a procedure that delivers a chemotherapeutic agent to a tumor along with sponge particles that have an ischemic effect on the mass. (
  • Chemotherapy is one of the most significant treatment options for patients with advanced HCC not indicated for hepatic resection, percutaneous ablation and transcatheter arterial chemoembolization. (
  • Therapeutic options consisting of ablation, chemoembolization or radioembolization designed specifically to relieve pain caused by primary or metastatic tumors. (
  • Treatment options for HCC include chemotherapy, chemoembolization, ablation and proton-beam therapy. (
  • There are many CHC therapies, some with curative intention (liver transplantation, surgical resection, ablation techniques), and some with palliative aims (chemoembolization). (
  • In a series of studies, the safety and effectiveness of HDR-BT has already been demonstrated, suggesting a potential as a bridging therapy to liver transplantation in addition to radiofrequency ablation or transarterial chemoembolization [9]. (
  • The risk of spreading malignant cells during diagnostic and therapeutic methods have been reported for liver biopsy and thermal ablation with heterogeneous results, also varying by the utility of needle track ablation [10,11,12,13]. (
  • As alternative to hepatic resection in patients with liver metastases, local ablative procedures may also be considered, including chemoembolization, laser, and radiofrequency ablation, as palliative support to control symptoms of hypersecretion syndrome ( 6 ). (
  • In the first study of its kind, the researchers combined sorafenib, the only Food and Drug Administration-approved pill for treating advanced liver cancer, with another routinely used therapy known as transarterial chemoembolization, which works by cutting off the blood supply to tumors. (
  • Researchers believe that adding sorafenib to the mix could help offset that tumor-friendly activity and improve the therapeutic action of the initial therapy. (
  • Drug exposure of mesenchymal HCC cells showed higher resistance to the targeted therapeutic agents sorafenib and erlotinib as compared to epithelial HCC cells, which were slightly more resistant to cytostatic drugs. (
  • Moreover, targeted therapeutic agents such as the multikinase inhibitor sorafenib (Nexavar) have been shown to have survival benefits especially in patients with advanced stage HCC ( 15-17 ). (
  • The therapeutic response of 156 patients with advanced HCC who had been treated with sorafenib therapy for more than 1 month was evaluated using the RECIST1.1, mRECIST, and RECICL. (
  • Sorafenib represents the therapeutic stronghold in advanced HCC patients. (
  • The complexity of the tumor prevents the major goal of this therapeutic approach, since sorafenib, a multi-kinase inhibitor, is the only successful drug so far that belongs to the target directed therapy in advanced stage HCC. (
  • Transpulmonary chemoembolization (TPCE) is a locoregional technique for delivering chemotherapy in higher intratumoral concentrations and with reduced systemic toxicity. (
  • In addition, Interventional Oncology provides a range of therapeutic options used for palliative care including biopsy, vascular port, and chemotherapy catheter placement, abscess drainage, stenting of malignant strictures, and various therapies for pain relief. (
  • MLT exerts positive influence in tumor therapeutic strategies, including improving tumor remission rate and overall survival rate, while reducing the incidence of chemotherapy side effects. (
  • It has been reported that the concentration of chemotherapy within tumor tissue can be up to 100 times higher following chemoembolization than following systemic chemotherapy. (
  • Hepatic artery embolization , also known as trans-arterial embolization (TAE), is one of the several therapeutic methods to treat primary liver tumors or metastases to the liver. (
  • Further large-scale randomized clinical trials (RCTs) are urgently required to verify therapeutic effects of MLT in tumors by various clinical research centers. (
  • 2002. Carcinoid Tumors and the Carcinoid Syndrome: What's New in the Therapeutic Pipeline. (
  • The key to chemoembolization is the blood supply to liver tumors from branches of the hepatic artery. (
  • Therefore, locoregional therapies such as transarterial chemoembolization or radioembolization, can selectively be administered in the arteries that are supplying the tumors and will preferentially lead to deposition of the particles in the tumor, while sparing the healthy liver tissue from harmful side effects. (
  • Systematic central histopathological review of these tumors performed as part of pediatric collaborative therapeutic protocols has allowed the identification of histologic subtypes with distinct clinical associations. (
  • This minimally invasive procedure delivers therapeutic particles via a catheter to destroy tumors in the liver. (
  • Lakshmi N. Rajdev, MD, discusses classifying and grading neuroendocrine tumors (NETs), treating patients with NETs, and novel therapeutic strategies in the pipeline. (
  • Therefore, therapeutic options to inhibit the growth of metastatic GEP-NET tumors are still unsatisfactory and many patients become refractory to the conventional palliative therapy. (
  • For unresectable metastatic NETs, selective embolisation of the hepatic arteries may be therapeutic. (
  • However, hypoxia or ischemia always accompanies and then follows these HCC therapies and heavily affects the therapeutic outcomes. (
  • Hepatic resection and transarterial chemoembolization were frequent first-line therapies. (
  • The most frequent therapy was hepatic resection for patients with BCLC-0/A/B disease, and transarterial chemoembolization for patients with BCLC-C disease. (
  • To retrospectively evaluate tumor response, local tumor control, and patient survival after the treatment of pulmonary metastases using transpulmonary chemoembolization (TPCE) in palliative and neoadjuvant intent. (
  • Conventional transarterial chemoembolization (cTACE) is widely used as a palliative treatment for inoperable HCC. (
  • In these cases, there are relatively few therapeutic options and most of them are palliative. (
  • 5-Fluorouracil was incorporated in the matrix for the possible use of the microspheres in chemoembolization. (
  • Percutaneous transhepatic portal chemoembolization (PTPCE) performed 4 days after the cell inoculation, resulted in prolonging the survival time, inhibiting the tumor growth, and suppressing the intrahepatic metastasis in comparison with control animals. (
  • HAIC provides moderate therapeutic efficacy and survival benefit with substantially tolerable toxicity profiles in patients with advanced HCC. (
  • 2 Tumor characteristics in form of size, number of lesions and vascular invasion and host characteristics in form of Child's status of liver disease and overall performance status of the patient dictates the therapeutic options and its outcome. (
  • Due to the high blood perfusion of primary pPNETs and high RGD uptake by the primary and metastatic lesions, chemoembolization and anti‑angiogenic therapy were considered to be the optimal therapeutic choice. (
  • Multicenter studies investigating the long-term outcomes of currently available therapeutic options in the thalassemia realm, in addition to novel HCC therapeutic targets, are needed to further improve the prognosis of these patients. (
  • Most HCC patients are diagnosed at an advanced stage with few therapeutic measures. (
  • Most patients with advanced cancer confined to the liver are given a treatment called transarterial chemoembolization. (
  • We reported the therapeutic effects of TATI in four patients with advanced HCC. (
  • Finally the management of acute liver failure has certainly evolved with new therapeutic options such as liver assist devices that can help manage these patients in the intensive care unit. (
  • So, strategies to inhibit AEG-1 that could lead to the shutdown of these pathways, either by small molecules or by siRNAs, might be an important therapeutic modality for HCC patients," said principal investigator Devanand Sarkar, Ph.D., MBBS, assistant professor in the Department of Human and Molecular Genetics in the VCU School of Medicine, and Harrison Endowed Scholar in Cancer Research at the VCU Massey Cancer Center. (
  • In an interview during the 2019 OncLive ® State of the Science Summit™ on Gastrointestinal Cancers, Rajdev, an associate professor, Department of Medicine (Oncology), at Albert Einstein College of Medicine, Montefiore Medical Center, discussed classifying and grading NETs, treating patients with NETs, and novel therapeutic strategies in the pipeline. (
  • Interventional radiology techniques typically represent the least invasive definitive diagnostic or therapeutic options available for patients with cancer. (
  • Given the correlation between LDH levels and tumour angiogenesis we can speculate that patients with high LDH pretreatment levels may be optimal candidates for other emerging therapeutic agents or strategies targeting different molecular pathways. (
  • The incidence of delayed gastric emptying (DGE) is high in patients undergoing distal pancreatectomy with celiac axis en-bloc resection (DP-CAR). (
  • Substantial evidence has revealed that both tissue and circulating circRNAs may serve as potential biomarkers for diagnostic, prognostic and therapeutic purposes. (
  • The incorporation of new diagnostic and therapeutic interventions in clinical hepatology as well as liver transplantation has exponentially grown and specialty fields have emerged within the liver disease arena. (
  • Other commonly performed intervention is digestive and hepatobiliary endoscopy which offers not only diagnostic but also therapeutic choices in various areas such as portal hypertension and hepatobiliary disease. (
  • It poses a diagnostic challenge to the pathologists and often poses a therapeutic dilemma for the oncologists . (
  • Polymeric particles are provided for use in therapeutic and/or diagnostic procedures. (
  • A further subdivision is the diagnostic versus therapeutic specialties. (
  • Interventional radiology offers minimally invasive diagnostic and therapeutic procedures for cancer and cancer-related processes. (
  • In this context, the discovery of the central role of microRNAs (miRNA) in human tumorigenesis has opened a new field that may be relevant not only for understanding cancer at the molecular level but also for the development of new diagnostic and therapeutic tools. (
  • The most common single chemo-therapeutic agent is doxorubicin. (
  • These tiny drug-delivery agents, made from biodegradable polymer and measuring 50 micrometers in diameter - just under the breadth of a hair - encapsulate a dose of a therapeutic agent (in this case, doxorubicin) as well as magnetic nanoparticles. (
  • In addition, in a therapeutic perspective, we assayed the effects of a restored miR-122 expression in triggering doxorubicin-induced apoptosis and we proved that miR-122, as well as cyclin G1 silencing, increases sensitivity to doxorubicin challenge. (
  • Not only does reduced blood flow prevent washout of chemo-therapeutic agents, but tumor ischemia has been shown to cause failure of transmembrane pumps in tumor cells, 8 resulting in an even greater retention of chemo- therapeutic agents. (
  • Finally, the full arsenal of therapeutic approaches is presented, from the local to systemic, established to experimental. (
  • Combining targeted drugs or immunotherapies with conventional therapeutic approaches may provide synergistic effects and facilitate the development of personalized medicine. (
  • Despite recent advancements, new more effective therapeutic approaches are urgently needed. (
  • In recent years, lenvatinib and anti-PD-1 have exhibited potential therapeutic effects for advanced HCC. (
  • In conclusion, NONO functioned as a multipurpose scaffold that interacted with HIF-1/2 complex and their downstream transcripts to facilitate the expression of hypoxia-induced genes, allowing malignant proliferation, indicating that NONO might be a potential therapeutic target for HCC. (
  • This is a medical first that will help improve chemoembolization, a current treatment for liver cancer. (
  • Additionally, both the fields of hepatology and endoscopy have become very specialized and thus a thorough knowledge of the indications, findings, therapeutic possibilities and complications that arise from endoscopic interventions is a must for the practicing clinician. (
  • Magnetic resonance navigation (MRN) involving the endovascular steering of therapeutic magnetic microcarriers (TMMC) represents a clinically viable alternative to reach deep tissues. (
  • Taken together, this EMT model of human HCC allows the identification of molecular mechanisms and the assessment of therapeutic drug efficacy during liver cancer progression in preclinical studies. (
  • The RECICL should, therefore, be considered a superior system for assessment of therapeutic response. (
  • Early correct diagnosis and accurate staging are crucial for selecting the optimal therapeutic regimens ( 7 ). (
  • This study aims to investigate the therapeutic potential and mechanism of curcumin in breast cancer. (